



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Dexrazoxane

Cat. No.:	HY-B0581
CAS No.:	24584-09-6
Molecular Formula:	C ₁₁ H ₁₆ N ₄ O ₄
Molecular Weight:	268.27
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (93.19 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.7276 mL	18.6379 mL	37.2759 mL
		5 mM		0.7455 mL	3.7276 mL	7.4552 mL
		10 mM		0.3728 mL	1.8638 mL	3.7276 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Dexrazoxane (ICRF-187) is a cardioprotective agent. Target: Others Dexrazoxane is a cardioprotective agent. Dexrazoxane is a derivative of EDTA, dexrazoxane chelates iron and thus reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. The exact chelation mechanism is unknown, but it has been postulated that dexrazoxane can be converted into ring-opened form intracellularly and interfere with iron-mediated free radical generation that is in part thought to be responsible for anthracycline induced cardiomyopathy. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs [1, 2].
-------------	--

CUSTOMER VALIDATION

- Nat Med. 2016 May;22(5):547-56.
- Adv Sci (Weinh). 2023 Mar 26;e2206007.
- Nano Res. 2023 Apr 18.
- Phytomedicine. 2023 Jun 10, 154922.
- Biomed Pharmacother. 2022 Jun 17;153:113280.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Jones, R.L., Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther, 2008. 6(10): p. 1311-7.
- [2]. Loyevsky, M., et al., Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol, 1999. 91(2): p. 105-14.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA